Protara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	14.74	49.66	162.8	39.59	24.13	35.72
Short-Term Investments	121.05	105.9	7.49	25.99	60.24	55.51
Cash & Short-Term Investments	135.79	155.55	170.29	65.58	84.37	91.23
Cash Growth	9.19%	-8.65%	159.67%	-22.27%	-7.52%	-45.89%
Other Current Assets	4.21	3.95	1.86	3.13	1.78	1.88
Total Current Assets	140	159.5	172.16	68.71	86.15	93.11
Net Property, Plant & Equipment	3.56	3.93	5.28	6.56	7.87	8.89
Goodwill	-	-	-	-	-	29.52
Long-Term Investments	41.64	42.34	-	-	17.89	39.47
Other Long-Term Assets	6.73	3.7	4.02	3.69	1.39	1.61
Total Assets	191.92	209.47	181.45	78.95	113.29	172.6
Accounts Payable	4.03	3.47	4.43	2.43	1.59	0.95
Accrued Expenses	3.63	6.23	5.41	2.73	3.24	2.49
Current Portion of Leases	1.26	1.24	1.12	0.98	0.92	0.86
Total Current Liabilities	8.92	10.94	10.96	6.15	5.74	4.3
Long-Term Leases	1.79	2.12	3.36	4.48	5.47	6.38
Total Long-Term Liabilities	1.79	2.12	3.36	4.48	5.47	6.38
Total Liabilities	10.72	13.06	14.32	10.63	11.21	10.68
Shareholders' Equity	181.21	196.41	167.13	68.32	102.08	161.91
Total Liabilities & Equity	191.92	209.47	181.45	78.95	113.29	172.6
Total Debt	3.06	3.36	4.48	5.47	6.38	7.24
Net Cash (Debt)	132.73	152.2	165.81	60.11	77.99	83.99
Net Cash Growth	-12.79%	-8.21%	175.83%	-22.92%	-7.15%	-49.86%
Net Cash Per Share	2.82	3.55	8.05	5.30	6.93	7.48
Book Value	181.21	196.41	167.13	68.32	102.08	161.91
Book Value Per Share	3.85	4.59	8.12	6.03	9.07	14.41
Tangible Book Value	181.21	196.41	167.13	68.32	102.08	132.4
Tangible Book Value Per Share	3.85	4.59	8.12	6.03	9.07	11.79

SEC Filings: 10-K · 10-Q